SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) — Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors.
“We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a deep understanding and successful track record in strategy and execution in global clinical development and medical affairs,” stated Kevin R. Lind, Longboard’s President and Chief Executive Officer. “These attributes will be invaluable as we advance and expand our robust pipeline and continue to build a world-class team.”
Dr. Tiller currently serves as Chief Medical Officer of Neumora Therapeutics, a position she has held since Neumora acquired BlackThorn Therapeutics, where she had served as Chief Medical Officer. Prior to BlackThorn, Dr. Tiller was Head of Medical European Markets, Australia and Canada at Bristol-Myers Squibb (BMS), where she oversaw all medical functions for her territories. During her tenure at BMS, Dr. Tiller also served as Vice President of Global Medical for neuroscience, virology and immunoscience, and as Vice President, Full Development Gamma Secretase for BMS’ Alzheimer’s program. Previously, she held positions of increasing responsibility at Cephalon, including as Vice President, Clinical Research, CNS/Pain, where she was responsible for all clinical development activities of programs for schizophrenia, bipolar disorder, anxiety and sleep disorders. Prior to joining industry, Dr. Tiller was Clinical Director at the Maudsley Hospital, London, a Consultant Psychiatrist (attending) and honorary Senior Lecturer. Dr. Tiller received her medical degree from the Glasgow University Medical School, an M.B.A. from Drexel University, and an MPhil from the University of Pennsylvania.
About Longboard Pharmaceuticals
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard is working to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard’s small molecule product candidates are based on more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting 5-HT2c receptor superagonist, with negligible observed impact on 5-HT2b and 5-HT2a receptor subtypes, in development for the potential treatment of seizures associated with developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full CB2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, S1P receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Longboard’s clinical and preclinical programs, ability to advance our pipeline and develop medicines, attributes, building of our team, and focus. For such statements, Longboard claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Longboard’s expectations. Factors that could cause actual results to differ materially from those stated or implied by Longboard’s forward-looking statements are disclosed in Longboard’s filings with the Securities and Exchange Commission (SEC). These forward-looking statements represent Longboard’s judgment as of the time of this release. Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
CONTACT: Corporate Contact: Megan E. Knight Head of Investor Relations [email protected] [email protected] 619.592.9775